In response to major changes in diagnostic algorithms and the publication of mature results
from various large clinical trials, the European Association of Neuro-Oncology (EANO) …

Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …

Immune-mediated anti-tumoral responses, elicited by oncolytic viruses and augmented with
checkpoint inhibition, may be an effective treatment approach for glioblastoma. Here in this …

Background Nearly all patients with newly diagnosed glioblastoma experience recurrence
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …

Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival
(OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with …

Background Effective treatments are needed to improve outcomes for high-grade glioma
and low-grade glioma. The activity and safety of dabrafenib plus trametinib were evaluated …

Abstract Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of
diffuse glioma,–. The most common IDH1 mutation in gliomas affects codon 132 and …

Importance Clinical outcomes for glioblastoma remain poor. Treatment with immune
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from …

BRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade
glioma (pLGG). Arm 1 (n= 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial …